Trend towards decreased survival in patients infected with HIV resistant to zidovudine.
The survival of 35 patients with AIDS or advanced HIV infection on treatment with zidovudine was related to the viral sensitivity to the drug and to the CD4+ cell count. 14 patients died, the survivors were followed up for an average of 804 days. In a univariate Cox model, survival was strongly related to log IC90 (p = 0.0003) and to the CD4+ count (p = 0.0002). In a bivariate model, log IC90 and the CD4+ count contributed to the prediction of survival (p = 0.12 and 0.06, respectively). Large studies of combination or alternation therapy with several anti-HIV drugs should be given high priority.
Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.
P C
PC
Gøtzsche
C
C
Nielsen
J
J
Gerstoft
C M
CM
Nielsen
B F
BF
Vestergaard
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D000328:Adult; D015496:CD4-Positive T-Lymphocytes; D004311:Double-Blind Method; D004352:Drug Resistance, Microbial; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D015996:Survival Rate / Q000639:trends; D015215:Zidovudine / Q000627:therapeutic use*
D015215:Zidovudine